(Reuters) – Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion (£10.3 billion)acquisition of Celgene Corp’s psoriasis therapy Otezla.
Bristol-Myers Squibb Co <BMY.N>, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through.
Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.
Full-year revenue is now expected between $23.1 billion and $23.3 billion, compared with the previous range of $22.8 billion to $23.0 billion.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)